dr. wirth on the use of lenvatinib in hypertensive patients with thyroid cancer
Published 6 years ago • 1.2K plays • Length 1:28Download video MP4
Download video MP3
Similar videos
-
2:07
dr. wirth discusses the safety profile of lenvatinib as seen in the select trial
-
0:53
dr. wirth on takeaways from the select trial in thyroid cancer
-
3:37
dr. wirth discusses the results of the select trial in thyroid cancer
-
1:46
dr wirth on the full fda approval of selpercatinib for advanced ret fusion thyroid cancer
-
1:23
dr. brose discusses lenvatinib for the treatment of patients with thyroid cancer
-
1:59
effect of age and lenvatinib treatment on os for patients with thyroid cancer
-
1:39
dr. bastholt on lenvatinib in thyroid cancer
-
12:22
bridging therapy with tenecteplase or alteplase in patients with large ischemic core
-
6:47
lenvatinib: new kid on the block
-
2:47
dr. wirth discusses the open-label extension of select
-
1:59
dr. cohen on lenvatinib in first- or second-line thyroid cancer
-
2:47
dr. brose discusses lenvatinib and sorafenib in differentiated thyroid cancer
-
0:43
managing hypertension and thyroid cancer
-
1:17
expectations for the treatment landscape of differentiated thyroid cancers in the future
-
6:53
sequencing in dtc: lenvatinib and sorafenib
-
0:57
dr. taylor discusses the toxicities and impact of lenvatinib in the select trial
-
8:28
lenvatinib in advanced dtc
-
1:46
dr. bible on impact of lenvatinib on treatment landscape of dtc
-
1:00
lenvatinib in thyroid cancer with and without vegf-targeted therapy